



**FOR IMMEDIATE RELEASE**

**Rheonix, Inc. Announces Novel Microarray Production Technology to Support Multiplexed Endpoint Detection of Single Nucleotide Polymorphisms**

**Ithaca, NY – December 15, 2011** – Rheonix today announced that it has completed development of a novel microarray production technology to create a high-fidelity microarray, the Hy-Fi Microarray™. Hy-Fi Microarrays provide simple, multiplexed end point detection for molecular assays and, in particular, a novel method to detect single nucleotide polymorphisms (SNPs) on the Rheonix CARD® system. While Rheonix intends to apply this proprietary microarray technology to improve SNP detection, the technology is broadly applicable to meet the need for high volume production of high quality/low density microarrays and therefore, has licensing potential for use in multiple research and clinical applications. Together, these new technology components will allow Rheonix to produce higher quality and more accurate diagnostic results.

“We have integrated all of the key components for molecular diagnostics into a compact, automated platform – raw sample prep, molecular amplification and analysis,” said Tony Eisenhut, President of Rheonix. “The addition of the Hy-Fi Microarray to our system provides an accurate, easy to use end-point analytical tool, with the added significant benefit of low production costs for Rheonix and potential partners.”

Rheonix’s novel microarray production technology produces DNA and RNA, as well as protein, spots for an entire array in a single print, while simultaneously controlling for spot morphology and reducing array-to-array variation of the spots, thus ensuring the reproducibility of the microarray results. Using this technology, Rheonix has created Hy-Fi Microarrays, which could provide more accurate results than traditional microarrays. The Hy-Fi Microarray is further improved with the use of Locked Nucleic Acids (“LNAs”) under license from Exiqon A/S for SNP assays where the LNA’s improve the fidelity of the base pairing to exclude non-specific base pair hybridization. LNAs provide a high signal-to-noise ratio, making the microarray’s results easier to interpret. The Rheonix microarray production process is powerful, adaptable and scalable, enabling benefits for both Rheonix and potential partners. Rheonix has initially configured the system for its own high volume microarray printing; however, it can be easily adjusted for custom microarray production using the same processes. The system’s components are user-friendly and robust, providing long service life to the research lab or production environment at a reasonable cost. Together, with the increased accuracy of results and low cost, these technology components will bring great value to Rheonix.

**About Rheonix**



Rheonix has created a powerful microfluidic platform for the evolving molecular diagnostics industry. This system incorporates low cost disposable Rheonix CARD® technology to analyze single or multiple clinical raw samples. The Rheonix CARD® system provides multiplexed endpoint analysis and can be rapidly customized for a wide breadth of diagnostic applications.

[www.rheonix.com](http://www.rheonix.com)

###

**Contacts:**

Tony Eisenhut, President  
Rheonix, Inc.:  
607-257-1242, ext. 160

Media Contact:  
Douglas MacDougall or Michelle Avery  
MacDougall Biomedical Communications  
781-235-3060